Drug Trial Radar · NCT06716151
A Study to Evaluate HB0034 in Healthy Chinese Adult Participants
Last checked: Nov 19, 2026Latest source record: Jan 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Dec 6, 2024
Primary completion
Nov 20, 2025
Study completion Nov 20, 2025
Sponsor
- Lead sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The aim of this study is to investigate the safety and tolerability of HB0034 in healthy subjects following a single dose or multiple dose.
Conditions
- Healthy
Interventions
HB0034Drug
Recombinant Humanized Anti-IL-36R Monoclonal antibody
HB0034 matching placeboDrug
HB0034 matching Palcebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of subjects with drug related adverse events (AEs)Time frame: up to 113 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Central Hospital affiliated to Shandong First Medical University
Jinan, Shandong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.